Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic art… Read more
Market Cap & Net Worth: Alvotech (ALVO)
Alvotech (NASDAQ:ALVO) has a market capitalization of $1.19 Billion ($1.19 Billion) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11196 globally and #5043 in its home market, demonstrating a -4.98% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Alvotech's stock price $3.82 by its total outstanding shares 311601154 (311.60 Million).
Alvotech Market Cap History: 2020 to 2026
Alvotech's market capitalization history from 2020 to 2026. Data shows change from $3.27 Billion to $1.19 Billion (-16.06% CAGR).
Index Memberships
Alvotech is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.24 Trillion | 0.02% | #306 of 976 |
|
NASDAQ Composite
IXIC
|
$33.39 Trillion | 0.00% | #1125 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.54 Trillion | 0.03% | #175 of 263 |
Weight: Alvotech's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Alvotech Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Alvotech's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.42x
Alvotech's market cap is 8.42 times its annual revenue
1.02x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $3.27 Billion | $66.62 Million | -$170.04 Million | 49.07x | N/A |
| 2021 | $3.08 Billion | $36.77 Million | -$101.50 Million | 83.72x | N/A |
| 2022 | $3.12 Billion | $83.03 Million | -$513.58 Million | 37.53x | N/A |
| 2023 | $3.58 Billion | $91.43 Million | -$551.73 Million | 39.12x | N/A |
| 2024 | $4.12 Billion | $489.68 Million | -$231.86 Million | 8.42x | N/A |
Competitor Companies of ALVO by Market Capitalization
Companies near Alvotech in the global market cap rankings as of March 19, 2026.
Key companies related to Alvotech by market ranking:
- Zoetis Inc (NYSE:ZTS): Ranked #410 globally with a market cap of $53.52 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #434 globally with a market cap of $49.87 Billion USD.
- Takeda Pharmaceutical Co. Ltd. (PINK:TKPHF): Ranked #457 globally with a market cap of $47.47 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #721 globally with a market cap of $28.19 Billion USD ( CN¥206.84 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #410 | Zoetis Inc | NYSE:ZTS | $53.52 Billion | $121.68 |
| #434 | Haleon plc | NYSE:HLN | $49.87 Billion | $10.60 |
| #457 | Takeda Pharmaceutical Co. Ltd. | PINK:TKPHF | $47.47 Billion | $30.07 |
| #721 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $28.19 Billion | CN¥55.11 |
Alvotech Historical Marketcap From 2020 to 2026
Between 2020 and today, Alvotech's market cap moved from $3.27 Billion to $ 1.19 Billion, with a yearly change of -16.06%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.19 Billion | -25.54% |
| 2025 | $1.60 Billion | -61.22% |
| 2024 | $4.12 Billion | +15.24% |
| 2023 | $3.58 Billion | +14.80% |
| 2022 | $3.12 Billion | +1.21% |
| 2021 | $3.08 Billion | -5.82% |
| 2020 | $3.27 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Alvotech was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.19 Billion USD |
| MoneyControl | $1.19 Billion USD |
| MarketWatch | $1.19 Billion USD |
| marketcap.company | $1.19 Billion USD |
| Reuters | $1.19 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.